Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Abstract Background To assess the effect of switching patients previously incompletely treated with ranibizumab (RBZ) to aflibercept (AFL) using a pro re nata (PRN) treatment strategy in neovascular age-related macular degeneration (nvAMD). Methods A retrospective case series was conducted on patien...

Full description

Bibliographic Details
Main Authors: Flora Elwes, Shyamanga Borooah, Peter Aspinall, Peng Yong Sim, Cheng Yi Loo, Ana-Maria Armbrecht, Baljean Dhillon, Peter Cackett
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Ophthalmology
Subjects:
Age-related macular degeneration
Ranibizumab
Aflibercept
Anti-VEGF
Online Access:http://link.springer.com/article/10.1186/s12886-018-0688-3

Internet

http://link.springer.com/article/10.1186/s12886-018-0688-3

Similar Items